Takeda Pharmaceutical Company share price today
(NASDAQ: TAK)

Name: Takeda Pharmaceutical Company Share Price Today (NASDAQ: TAK) - Takeda Pharmaceutical Company Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Takeda Pharmaceutical Company share price is $12.92 & ₹1,117.45 as on 24 Jan 2025, 2.30 'hrs' IST

$12.92

▲

0.03

(0.23%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Takeda Pharmaceutical Company share price in Dollar and Rupees. Guide to invest in Takeda Pharmaceutical Company stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Takeda Pharmaceutical Company, along with analyst recommendations, forecasts, and comprehensive financials.

Takeda Pharmaceutical Company share price movements

Today's Low: $12.82
Today's High: $12.95
$12.92
0.77%
Downside
Day's Volatility :1.0%
Upside
0.23%
52 Weeks Low: $12.58
52 Weeks High: $15.08
$12.92
2.67%
Downside
52 Weeks Volatility :16.61%
Upside
14.32%

Takeda Pharmaceutical Company Returns

Period	Takeda Pharmaceutical Company Limited	Sector (Health Care)	Index (Russel 2000)
3 Months	-4.79%	-4.8%	0.0%
6 Months	-6.39%	-5.1%	0.0%
1 Year	-11.69%	2.5%	0.0%
3 Years	-11.23%	10.2%	-13.0%

Takeda Pharmaceutical Company Key Statistics

in dollars & INR

Previous Close	$12.89
Open	$12.85
Today's High	$12.95
Today's Low	$12.82
Market Capitalization	$41.5B
Today's Volume	$2.9M
52 Week High	$15.08
52 Week Low	$12.575
Revenue TTM	$4.5T
EBITDA	$1.3T
Earnings Per Share (EPS)	$0.59
PE Ratio	22.2
Dividend Yield	5.05%
Profit Margin	6.38%
Quarterly Earnings Growth YOY	0.05%
Return On Equity TTM	4.15%

How to invest in Takeda Pharmaceutical Company Stock (TAK) from India?

It is very easy for Indian residents to invest directly in Takeda Pharmaceutical Company from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Takeda Pharmaceutical Company stock in both Indian Rupees (INR) and US Dollars (USD). Search for Takeda Pharmaceutical Company or TAK on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Takeda Pharmaceutical Company or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Takeda Pharmaceutical Company shares which would translate to 0.067 fractional shares of Takeda Pharmaceutical Company as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Takeda Pharmaceutical Company, in just a few clicks!

Returns in Takeda Pharmaceutical Company for Indian investors in Rupees

Investment Value

₹1,00,000

Takeda Pharmaceutical Company investment value today

Current value as on today

₹92,421

Returns

₹7,579

(-7.58%)

Returns from Takeda Pharmaceutical Company Stock

₹11,688 (-11.69%)

Dollar Returns

₹4,109 (+4.11%)

Indian investors sentiment towards Takeda Pharmaceutical Company

-24%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Takeda Pharmaceutical Company on INDmoney from India has reduced in the last 30 days as on Jan 24, 2025. -24% less investors are searching Takeda Pharmaceutical Company in the last 30 days versus the previous period.

Global Institutional Holdings in Takeda Pharmaceutical Company

Capital Research Global Investors
0.41%
Morgan Stanley - Brokerage Accounts
0.17%
Mondrian Investment Partners Ltd
0.16%
Arrowstreet Capital Limited Partnership
0.15%
Goldman Sachs Group Inc
0.14%
Millennium Management LLC
0.11%

Analyst Recommendation on Takeda Pharmaceutical Company

Buy

52%Buy

47%Hold

0%Sell

Based on 23 Wall street analysts offering stock ratings for Takeda Pharmaceutical Company(by analysts ranked 0 to 5 stars)

Based on 23 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Takeda Pharmaceutical Company

What analysts predicted

Upside of 22.83%

Target:

$15.87

Current:

$12.92

Insights on Takeda Pharmaceutical Company

Price Movement
In the last 7 days, TAK stock has moved down by -0.2%
Decreasing Revenue
Takeda Pharmaceutical Company Limited has experienced a decline in revenue for the last two quarters. Revenue fell from $1207.99 billion to $1176.03 billion, reflecting an average decrease of 2.7% per quarter.
Decreasing Net Profit
Takeda Pharmaceutical Company Limited has experienced a decline in net profit over the last two quarters. The net profit fell from $95.24 billion to $92.04 billion, resulting in an average decrease of 3.4% per quarter.
TAK vs ITCI (1 yr)
In the last 1 year, Intra-cellular Therapies, Inc. has given 92.4% return, outperforming this stock by 104.6%
TAK vs ITCI (3 yr)
In the last 3 years, Intra-cellular Therapies, Inc. has given 186.8% return, outperforming this stock by 197.8%
Price to Sales
Takeda Pharmaceutical Company Limited currently has a Price-to-Sales Ratio of $0.0, meaning that investors are not willing to pay anything for each dollar of sales the company generates. In contrast, Intra-cellular Therapies, Inc. has a significantly higher Price-to-Sales Ratio of $20.8, indicating that investors are willing to pay $20.8 for every dollar of sales. This suggests that investors have markedly different perceptions of the value of these two companies based on their sales performance.

Takeda Pharmaceutical Company Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$18.9B	↑ 18.45%
Net Income	$981.7M	↓ 41.61%
Net Profit Margin	5.2%	↓ 5.36%

	FY20	Y/Y Change
Revenue	$30.6B	↑ 56.93%
Net Income	$411.6M	↓ 59.46%
Net Profit Margin	1.34%	↓ 3.86%

	FY21	Y/Y Change
Revenue	$29.4B	↓ 2.84%
Net Income	$3.5B	↑ 749.9%
Net Profit Margin	11.76%	↑ 10.42%

	FY22	Y/Y Change
Revenue	$30.2B	↑ 11.61%
Net Income	$1.9B	↓ 38.81%
Net Profit Margin	6.45%	↓ 5.31%

	FY23	Y/Y Change
Revenue	$30.1B	↑ 12.85%
Net Income	$2.4B	↑ 37.8%
Net Profit Margin	7.87%	↑ 1.42%

	FY24	Y/Y Change
Revenue	$28.5B	↑ 5.87%
Net Income	$961.7M	↓ 54.56%
Net Profit Margin	3.38%	↓ 4.49%

	Q2 FY23	Q/Q Change
Revenue	$7.4B	↑ 9.09%
Net Income	$-339.7M	↓ 254.27%
Net Profit Margin	-4.6%	↓ 7.86%

	Q3 FY23	Q/Q Change
Revenue	$7.1B	↑ 0.0%
Net Income	$-324.9M	↑ 0.0%
Net Profit Margin	-4.6%	↑ 0.0%

	Q4 FY23	Q/Q Change
Revenue	$7.7B	↑ 6.53%
Net Income	$735.0M	↓ 320.11%
Net Profit Margin	9.51%	↑ 14.11%

	Q1 FY24	Q/Q Change
Revenue	$7.0B	↓ 5.43%
Net Income	$-20.1M	↓ 102.85%
Net Profit Margin	-0.29%	↓ 9.8%

	Q2 FY24	Q/Q Change
Revenue	$7.6B	↑ 14.95%
Net Income	$602.7M	↓ 3256.0%
Net Profit Margin	7.88%	↑ 8.17%

	Q3 FY24	Q/Q Change
Revenue	$1.2T	↓ 2.65%
Net Income	$92.0B	↓ 3.36%
Net Profit Margin	7.83%	↓ 0.05%

	FY19	Y/Y Change
Profit	$12.9B	↑ 12.78%

	FY20	Y/Y Change
Profit	$20.5B	↑ 53.14%

	FY21	Y/Y Change
Profit	$20.3B	↑ 0.09%

	FY22	Y/Y Change
Profit	$20.8B	↑ 11.74%

	FY23	Y/Y Change
Profit	$20.8B	↑ 13.05%

	FY24	Y/Y Change
Profit	$18.9B	↑ 1.76%

	Q2 FY23	Q/Q Change
Profit	$4.9B	↑ 8.22%

	Q3 FY23	Q/Q Change
Profit	$4.7B	↑ 0.0%

	Q4 FY23	Q/Q Change
Profit	$5.1B	↑ 4.6%

	Q1 FY24	Q/Q Change
Profit	$3.2B	↓ 34.18%

	Q2 FY24	Q/Q Change
Profit	$4.2B	↑ 36.66%

	Q3 FY24	Q/Q Change
Profit	$639.3B	↓ 2.87%

	FY19	Y/Y Change
Operating Cash Flow	$3.0B	↓ 13.07%
Investing Cash Flow	$-25.5B	↑ 2937.97%
Financing Cash Flow	$26.5B	↓ 1003.13%

	FY20	Y/Y Change
Operating Cash Flow	$6.2B	↑ 103.89%
Investing Cash Flow	$2.7B	↓ 110.3%
Financing Cash Flow	$-9.4B	↓ 134.12%

	FY21	Y/Y Change
Operating Cash Flow	$9.3B	↑ 50.94%
Investing Cash Flow	$3.6B	↑ 34.72%
Financing Cash Flow	$-10.0B	↑ 8.27%

	FY22	Y/Y Change
Operating Cash Flow	$9.5B	↑ 11.1%
Investing Cash Flow	$-1.7B	↓ 150.35%
Financing Cash Flow	$-9.0B	↓ 1.66%

	FY23	Y/Y Change
Operating Cash Flow	$7.3B	↓ 13.0%
Investing Cash Flow	$-4.5B	↑ 206.42%
Financing Cash Flow	$-5.3B	↓ 33.74%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$1.4B	↓ 32.27%
Investing Cash Flow	$-1.9B	↓ 56.1%
Financing Cash Flow	$-994.8M	↑ 2031.14%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$1.3B	↑ 0.0%
Investing Cash Flow	$-2.2B	↑ 22.73%
Financing Cash Flow	$-951.5M	↑ 0.0%

Takeda Pharmaceutical Company Technicals Summary

Sell

Neutral

Buy

Takeda Pharmaceutical Company is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Takeda Pharmaceutical Company Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Takeda Pharmaceutical Company Limited	-1.67%	-6.39%	-11.69%	-11.23%	-34.52%
Intra-cellular Therapies, Inc.	47.85%	58.17%	89.83%	172.62%	447.12%
Haleon Plc Spon Ads	-5.34%	-0.11%	14.11%	24.43%	24.43%
Zoetis Inc.	0.67%	-7.35%	-11.05%	-14.66%	22.56%
Neurocrine Biosciences Inc.	5.56%	-0.03%	4.08%	93.28%	48.77%
Viatris Inc.	-11.31%	-7.78%	-5.11%	-24.11%	-31.82%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Takeda Pharmaceutical Company Limited	22.2	22.2	1.62	0.0	0.04	0.03	0.05	4365.91
Intra-cellular Therapies, Inc.	NA	NA	0.0	-0.7	-0.1	-0.07	NA	10.8
Haleon Plc Spon Ads	28.0	28.0	1.65	0.36	0.07	0.04	0.02	1.82
Zoetis Inc.	31.32	31.32	2.61	5.88	0.47	0.15	0.01	11.59
Neurocrine Biosciences Inc.	39.03	39.03	0.34	6.6	0.16	0.12	NA	26.87
Viatris Inc.	224.4	NA	0.07	2.69	-0.04	0.02	0.04	16.58

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Takeda Pharmaceutical Company Limited	Buy	$41.5B	-34.52%	22.2	6.38%
Intra-cellular Therapies, Inc.	Buy	$13.4B	447.12%	NA	-14.07%
Haleon Plc Spon Ads	Buy	$41.8B	24.43%	28.0	10.75%
Zoetis Inc.	Buy	$75.2B	22.56%	31.32	26.55%
Neurocrine Biosciences Inc.	Buy	$14.9B	48.77%	39.03	17.21%
Viatris Inc.	Hold	$13.5B	-31.82%	224.4	-5.87%

Takeda Pharmaceutical Company Dividend announcements

Takeda Pharmaceutical Company Dividends March, 2022
In the quarter ending March,2022. Takeda Pharmaceutical Company has declared dividend of $0.33
Read More

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Organization	Takeda Pharmaceutical Company
Employees	49281
CEO	Mr. Christophe Weber
Industry	Health Technology

Management People of Takeda Pharmaceutical Company

Name	Title
Mr. Christophe Weber	President, CEO & Representative Director
Dr. Seigo Izumo	Chair of Management Board
Mr. Milano Furuta	CFO & Director
Mr. Haruhiko Hirate	Member of Management Board
Mr. Salvatore Alesci M.D., Ph.D.	Member of Management Board and Head of R&D Global Science & Biomedical Policy
Norimasa Takeda	Chief Accounting Officer & Corporate Controller
Mr. Iwaaki Taniguchi	Senior Vice President of Corporate Finance & Controlling Department
Mr. Gabriele Ricci	Chief Data & Technology Officer
Mr. Christopher David O'Reilly	Global Head of Investor Relations & Global Finance
Mr. Yoshihiro Nakagawa	Global General Counsel

Important FAQs about investing in Takeda Pharmaceutical Company (TAK) from India :

What is Takeda Pharmaceutical Company share price today?

Takeda Pharmaceutical Company share price today stands at $12.92, Open: $12.85 ; Previous Close: $12.89 ; High: $12.95 ; Low: $12.82 ; 52 Week High: $15.08 ; 52 Week Low: $12.58. The stock opens at $12.85, after a previous close of $12.89. The stock reached a daily high of $12.95 and a low of $12.82, with a 52-week high of $15.08 and a 52-week low of $12.58.

Can Indians buy Takeda Pharmaceutical Company shares?

Yes, Indians can invest in the Takeda Pharmaceutical Company (TAK) from India.

With INDmoney, you can buy Takeda Pharmaceutical Company at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Takeda Pharmaceutical Company at zero transaction cost.

How can I buy Takeda Pharmaceutical Company shares from India?

It is very easy to buy Takeda Pharmaceutical Company from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Takeda Pharmaceutical Company be purchased?

Yes, you can buy fractional shares of Takeda Pharmaceutical Company with INDmoney app.

What are the documents required to start investing in Takeda Pharmaceutical Company stocks?

To start investing in Takeda Pharmaceutical Company, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.